Zynaxis and Genta Announce Research and Licensing Agreement for Zyn-Linker Conjugate Development

Zynaxis, Inc. and Genta Incorporated have signed a research and licensing agreement to develop conjugates using Zynaxis' proprietary Zyn-Linker technology and oligonucleotides from Genta. The agreement aims to enhance the uptake and biological activity of Genta's proprietary oligonucleotides. If the results are positive, the companies will proceed to a broader collaboration to develop clinically useful conjugates, with Zynaxis licensing its Zyn-Linker technology to Genta. This agreement is part of a series of collaborations established by Zynaxis in 1994 with companies interested in regulating gene expression or gene therapy.

Key Takeaways:

• The research and licensing agreement between Zynaxis and Genta focuses on developing conjugates using Zynaxis' Zyn-Linker technology and Genta's oligonucleotides.
• The goal of the collaboration is to improve the uptake and biological activity of Genta's proprietary oligonucleotides.
• If the results are positive, the companies will proceed to a broader collaboration to develop clinically useful conjugates.
• Zynaxis will license its Zyn-Linker technology to Genta for those therapeutic areas of interest to the company.
• This agreement is part of a series of collaborations established by Zynaxis in 1994 with companies interested in regulating gene expression or gene therapy.
• Genta's research is focused on the development of Anticode therapeutics, particularly for the treatment of restenosis, cancer, hair loss, and infectious disease.
• The Zyn-Linker-enhanced cellular delivery technology could play a major role in advancing Genta's Anticode therapeutics.
• Zynaxis is developing innovative therapeutic agents and diagnostic testing products using its core expertise in cell biology and synthetic chemistry.
• The company has therapeutic programs investigating the use of Zyn-Linker conjugates for certain types of cancer, restenosis following coronary artery angioplasty, and other applications.
• Zynaxis also develops and markets cellular diagnostic and research products for purposes of diagnosis and disease monitoring.

Statistics:

• 1994: the year in which Zynaxis established a series of collaborations with companies interested in regulating gene expression or gene therapy.
• 2: the number of companies (Zynaxis and Genta) entering the research and licensing agreement.
• Several: the number of therapeutic areas of interest for which Genta will take a license to Zynaxis' Zyn-Linker technology.
• Various: the number of clinical trials conducted on novel topical dermatological products developed by Genta.

Sources:

• Business Wire, "Zynaxis, Inc. and Genta Incorporated Announce Research and Licensing Agreement" (December 12, 1994)
• Zynaxis, Inc. and Genta Incorporated, Press Release (December 12, 1994)